Alzumab itolizumab regulatory update

Biocon said India's Drugs Controller General of India (DCGI) approved Alzumab itolizumab to treat chronic plaque psoriasis. The company plans to launch the humanized IgG1 mAb that inhibits CD6 in the country later this year. Biocon said the anti-CD6 mAb is a first-in-class therapy and is its second novel biologic developed at its biotech hub in Bangalore. The company, which could not be reached for details, said it will seek a global partner to develop the product. ...